The Asia Pacific TEO device market will expand rapidly over the forecast period, driven primarily by the large, underpenetrated patient pool in the region, increasing access to treatment due to improving health care systems in India and China, as well as the adoption of innovative products.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for TEO devices in the Asia Pacific region across a 10-year period.
The TEO device markets in India and China are underdeveloped compared to the Australian and South Korean markets.
What factors are responsible for low TEO procedure penetration in India and China?
How will recent health care reforms in these countries help to increase the adoption of TEO devices?
What strategies will competitors use in these markets to gain revenues?
The embolization particle market has seen many mergers and acquisitions.
What makes this market so dynamic and lucrative?
What competitive strategies are companies following when engaging in mergers and acquisitions in this space?
How will these mergers and acquisitions shape competitive dynamics in the Asia Pacific TEO embolization particle markets?
Companies with broad TEO product portfolios are more successful in this market.
Which competitors have the most comprehensive product portfolios?
How are competitors expanding their offerings through new product innovation and/or acquisition to capture more market share?
- Transcatheter Embolization And Occlusion Devices - Market Insights - Asia Pacific
Author(s): Ashish Bhupal, MBA
Ashish Bhupal is a manager within the Cardiovascular Medtech Insights team at DRG (Part of Clarivate), specializing in clot management, vascular access, aortic repair, heart valve, structural heart, interventional oncology, peripheral vascular, neurovascular, and transcatheter embolization and occlusion device markets. Ashish holds a Bachelor's in Biotechnology and an MBA in Biotechnology Management from Amity University, as well as a Six Sigma Green Belt certification from The British Standards Institution.
Follow Ashish on Twitter: @Ashishb_DRG.